



# House of Representatives

General Assembly

**File No. 120**

February Session, 2006

House Bill No. 5616

*House of Representatives, March 23, 2006*

The Committee on Public Health reported through REP. SAYERS of the 60th Dist., Chairperson of the Committee on the part of the House, that the bill ought to pass.

## ***AN ACT CONCERNING SCREENING FOR KIDNEY DISEASE.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1       Section 1. (NEW) (*Effective from passage*) (a) Beginning ninety days  
2 after the effective date of this section, any person, firm or corporation  
3 operating a clinical laboratory licensed in this state shall ensure that  
4 when the clinical laboratory tests a specimen to determine a patient's  
5 serum creatinine level, as ordered or prescribed by a health care  
6 professional authorized to make such an order or prescription, the  
7 clinical laboratory shall (1) calculate the patient's estimated glomerular  
8 filtration rate using the patient's age and gender, which information  
9 shall be provided to the clinical laboratory by the health care  
10 professional, and (2) include the patient's estimated glomerular  
11 filtration rate with its report to the health care professional. For  
12 purposes of this section, "clinical laboratory" has the same meaning as  
13 provided in section 19a-30 of the general statutes, and "patient" does  
14 not include any person under eighteen years of age.

15       (b) This section does not apply to serum creatinine level tests

16 conducted as part of a clinical trial or in furtherance of clinical  
17 research.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>from passage</i>	New section

**PH**      *Joint Favorable*

The following fiscal impact statement and bill analysis are prepared for the benefit of members of the General Assembly, solely for the purpose of information, summarization, and explanation, and do not represent the intent of the General Assembly or either House thereof for any purpose:

---

***OFA Fiscal Note***

***State Impact:*** None

***Municipal Impact:*** None

***Explanation***

It is anticipated that the University of Connecticut Health Center will incur minimal costs, which can be accommodated within its anticipated budget, to comply with the bill's reporting requirement.

No fiscal impact will result for the Department of Public Health.

***The Out Years***

***State Impact:*** None

***Municipal Impact:*** None

**OLR Bill Analysis**  
**HB 5616**

***AN ACT CONCERNING SCREENING FOR KIDNEY DISEASE.***

**SUMMARY:**

This bill imposes certain requirements on licensed clinical laboratories that test for kidney disease. A laboratory, when it tests a specimen to determine a patient's serum creatinine level (creatinine is a protein produced by muscle and released into the blood) as ordered by an authorized health professional, must: (1) calculate the patient's estimated glomerular filtration rate (GFR) using the patient's age and gender which the health care professional must provide and (2) include the patient's estimated GFR with its report to the health professional. Under the bill, a patient is someone age 18 and older.

GFR is a measure of how effectively the kidneys are removing waste and excess fluid from the blood. It is calculated based on a blood test for creatinine.

The bill's requirements must be met 90 days after its effective date. It also specifies that it does not apply to serum creatinine level tests conducted as part of a clinical trial or furthering research.

EFFECTIVE DATE: Upon passage

**CLINICAL LABORATORY**

Under the bill, a "clinical laboratory" is any facility or other area used for microbiological, serological, chemical, hematological, immunohematological, biophysical, cytological, pathological, or other examinations of human body fluids, secretions, excretions, or excised or exfoliated tissues, to provide information for the (1) diagnosis, prevention, or treatment of any human disease or impairment, (2) assessment of human health, or (3) presence of drugs, poisons, or other

toxicological substances (CGS Sec. 19a-30).

**COMMITTEE ACTION**

Public Health Committee

Joint Favorable

Yea 22      Nay 4      (03/10/2006)